• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Athira Pharma Inc.

    2/27/25 4:30:28 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATHA alert in real time by email
    S-8 1 atha_february_2025_s-8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S‑8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    ATHIRA PHARMA, INC.

    (Exact name of Registrant as specified in its charter)

     

     

    Delaware

     

    45-3368487

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

     

    18706 North Creek Parkway, Suite 104

    Bothell, WA 98011

    (Address of principal executive offices, including zip code)

     

     

    2020 Equity Incentive Plan
    2020 Employee Stock Purchase Plan

     

    (Full title of the plans)

     

     

    Mark Litton, Ph.D.

    President and Chief Executive Officer

    Athira Pharma, Inc.

    18706 North Creek Parkway, Suite 104

    Bothell, WA 98011

    (425) 620-8501

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Michael Nordtvedt

    Bryan D. King

    Wilson Sonsini Goodrich & Rosati,

    Professional Corporation

    701 Fifth Avenue, Suite 5100

    Seattle, WA 98104

    (206) 883-2500

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

     

     

     

     

     


    EXPLANATORY NOTE

    REGISTRATION OF ADDITIONAL SECURITIES

    PURSUANT TO GENERAL INSTRUCTION E

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by Athira Pharma, Inc. (the “Registrant”) for the purpose of registering (1) 1,952,047 shares of common stock of the Registrant reserved for issuance under the Athira Pharma, Inc. 2020 Equity Incentive Plan (the “2020 Plan”), pursuant to the provision of the 2020 Plan providing for such automatic increase in the number of shares reserved for issuance, and (2) 390,409 shares of common stock of the Registrant reserved for issuance under the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan (the “2020 ESPP”), pursuant to the provision of the 2020 ESPP providing for such automatic increase in the number of shares reserved for issuance. Accordingly, contents of the previous Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”), (1) September 18, 2020 (File No. 333-248910), (2) March 26, 2021 (File No. 333-254735), (3) March 28, 2022 (File No. 333-263907), (4) March 23, 2023 (File No. 333-270792), and (5) February 22, 2024 (File No. 333-277276) (together, the “Previous Forms S-8”), including the information incorporated by reference therein and the periodic reports filed after the Previous Forms S-8 to maintain current information about the Registrant, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

    (1) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025. pursuant to Section 13(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

    (2) All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Exchange Act (other than the reports, or portions thereof, deemed to have been furnished and not filed with the Commission) since the end of the fiscal year covered by the Annual Report referred to in (1) above; and

    (3) The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-39503) filed with the Commission on September 9, 2020, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 8. Exhibits.

     

    Exhibit

    Number

     

    Exhibit Description

     

    Form

     

     

    Incorporated by
    Reference

     

     

    Filing Date

     

     

     

     

     

     

     

     

    File No.

     

     

    Exhibit

     

     

     

     

     

     

     

     

     

     

    99.1

     

    Specimen common stock certificate of the Registrant

     

     

    S-1/A

     

     

     

    333-248428

     

     

     

    4.1

     

     

     

    September 14, 2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.2

     

    2020 Equity Incentive Plan

     

     

    S-1/A

     

     

     

    333-248428

     

     

     

    10.5

     

     

     

    September 8, 2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.3

     

    Form of Stock Option Agreement under the 2020 Equity Incentive Plan

     

     

    S-1/A

     

     

     

    333-248428

     

     

     

    10.6

     

     

     

    September 8, 2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.4

     

    Form of Restricted Stock Award Agreement under the 2020 Equity Incentive Plan

     

     

    S-1/A

     

     

     

    333-248428

     

     

     

    10.7

     

     

     

    September 8, 2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.5

     

    Form of RSU Agreement under the 2020 Equity Incentive Plan

     

     

    S-1/A

     

     

     

    333-248428

     

     

     

    10.8

     

     

     

    September 8, 2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.6

     

    2020 Employee Stock Purchase Plan, as amended and Form of Subscription Agreement thereunder

     

     

    10-K

     

     

     

    001-39503

     

     

     

    10.8

     

     

     

    March 23, 2023

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    5.1

     

    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.1

     

    Consent of Independent Registered Public Accounting Firm

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.2

     

    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    24.1

     

    Power of Attorney (contained on signature page hereto)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    107

     

    Filing Fee Table

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bothell, State of Washington, on February 27, 2025.

     

    ATHIRA PHARMA, INC.

     

     

    By:

     

    /s/ Mark Litton

     

     

    Mark Litton, Ph.D.

     

     

    President and Chief Executive Officer

     


    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark Litton and Robert Renninger, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement, including post-effective amendments, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully for all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

    /s/ Mark Litton

    Mark Litton

     

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

     

    February 27, 2025

     

     

     

    /s/ Robert Renninger

    Robert Renninger

     

    Senior Vice President, Finance and Accounting

    (Principal Accounting and Financial Officer)

     

    February 27, 2025

     

     

     

    /s/ Kelly A. Romano

    Kelly A. Romano

     

    Chair of the Board of Directors

     

    February 27, 2025

     

     

     

    /s/ Joseph Edelman

    Joseph Edelman

     

    Director

     

    February 27, 2025

     

     

     

    /s/ John M. Fluke, Jr.

    John M. Fluke, Jr.

     

    Director

     

    February 27, 2025

     

     

     

    /s/ James A. Johnson

    James A. Johnson

     

    Director

     

    February 27, 2025

     

     

     

     

     

    /s/ Barbara Kosacz

    Barbara Kosacz

     

    Director

     

    February 27, 2025

     

     

     

     

     

    /s/ Michael Panzara

    Michael Panzara

     

    Director

     

    February 27, 2025

     

     

     

     

     

    /s/ Grant Pickering

    Grant Pickering

     

    Director

     

    February 27, 2025

     


    Get the next $ATHA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATHA

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00 → $0.50Outperform → Neutral
    Mizuho
    9/4/2024Buy → Neutral
    Rodman & Renshaw
    9/4/2024Buy → Neutral
    BTIG Research
    9/4/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/19/2024$22.00Buy
    Rodman & Renshaw
    10/17/2022$20.00Mkt Perform → Mkt Outperform
    JMP Securities
    7/7/2022$6.00Buy
    Mizuho
    6/23/2022$36.00 → $5.00Buy → Hold
    Stifel
    More analyst ratings

    $ATHA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

      Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a clinical trial in ALS patients in late 2025 BOTHELL, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the Company will present data from a Phase 1 clinical trial of ATH-1105 in healthy volunteers at the 4th Annual ALS drug Development Summit taking place from May 1

      5/13/25 11:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

      Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in late 2025 BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2025, and provided recent pipeline and business updates. "We continue to focus our efforts on advancing ATH-1105 as a potential therapy for ALS. ATH-1105 has shown encouraging ev

      5/9/25 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

      Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2024, and provided recent pipeline and business updates. "We look forward to the opportunity to continue to advance ATH-1105 as a potential therapy for ALS, which in various preclinical models has demonstrated a consistent ability to

      2/27/25 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Romano Kelly A bought $100,051 worth of shares (42,400 units at $2.36), increasing direct ownership by 111% to 80,715 units (SEC Form 4)

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/25/24 7:21:55 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Perceptive Advisors Llc bought $1,462,895 worth of shares (605,686 units at $2.42) (SEC Form 4)

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      12/29/23 5:24:55 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Athira Pharma downgraded by Mizuho with a new price target

      Mizuho downgraded Athira Pharma from Outperform to Neutral and set a new price target of $0.50 from $5.00 previously

      9/19/24 7:34:53 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma downgraded by Rodman & Renshaw

      Rodman & Renshaw downgraded Athira Pharma from Buy to Neutral

      9/4/24 8:27:09 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma downgraded by BTIG Research

      BTIG Research downgraded Athira Pharma from Buy to Neutral

      9/4/24 7:28:38 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    SEC Filings

    See more
    • Athira Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Athira Pharma, Inc. (0001620463) (Filer)

      6/2/25 4:05:13 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Athira Pharma Inc.

      10-Q - Athira Pharma, Inc. (0001620463) (Filer)

      5/9/25 4:15:20 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Athira Pharma, Inc. (0001620463) (Filer)

      5/9/25 4:10:09 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fluke John M Jr

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/3/25 5:37:07 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Panzara Michael A.

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/3/25 5:36:21 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Romano Kelly A

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/3/25 5:35:41 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Athira Pharma Inc.

      SC 13G/A - Athira Pharma, Inc. (0001620463) (Subject)

      11/14/24 4:17:23 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Athira Pharma Inc.

      SC 13G - Athira Pharma, Inc. (0001620463) (Subject)

      11/7/24 1:15:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Athira Pharma Inc.

      SC 13D/A - Athira Pharma, Inc. (0001620463) (Subject)

      10/31/24 4:16:28 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Leadership Updates

    Live Leadership Updates

    See more
    • Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

      BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategies for multiple drugs across large and rare diseases with significant unmet medical need. "We are pleased to welcome Javier to the team and are confident his insights and guidance will be i

      4/15/24 7:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

      BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gengos replaces Glenna Mileson, who is retiring after serving as Athira's Chief Financial Officer for eight years. "On behalf of the entire Athira team, we thank Glenna for her many years of service, particularly for her stewardship during our transition to a publicly traded company, and wish her well in retirement," said Mark Litton, Ph.D

      5/22/23 7:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ric Kayne Publishes Investor Presentation Highlighting Urgent Need for Changes to Athira's Board of Directors

      New, Independent, Shareholder-Centric Directors are Needed to Ensure ATH-1017's Significant Potential is Realized and Reverse Destruction of Shareholder Value by Athira's Current Board Launches Campaign Website with Additional Information for Shareholders: www.SaveAthira.com Urges Athira Shareholders to VOTE their BLUE Proxy Card TODAY Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ:ATHA) ("Athira" or the "Company"), today released a detailed presentation to Athira's shareholders demonstrating the need for immediate change on the Company's Board of Directors (the "Board"

      4/25/22 8:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care